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A ﬂuorescent activatable probe for imaging
intracellular Mg2+ †
Ryan Treadwell,‡a Fabio de Moliner,‡a Ramon Subiros-Funosas,a Toby Hurd,b
Kirsten Knox c and Marc Vendrell *a
An activatable BODIPY probe for in vitro detection and ﬂuorescence cell imaging of free Mg2+ without
interference from Ca2+ is described. Fluorescence ampliﬁcation of the probe is observed upon detection
of physiological concentrations of Mg2+ due to reduced rotation of the ﬂuorophore and eﬀective chela-
tion by a quinolizine-based core.
Introduction
Intracellular magnesium (Mg2+) plays a crucial role in the phys-
iological activity of live cells. At concentrations below 30 mM,
Mg2+ is known to regulate and participate in a range of funda-
mental biological processes, including metabolic pathways,
DNA synthesis and being a co-factor for more than 600
enzymes. Consequently, the concentration of free unbound
intracellular Mg2+ falls to around 0.5–1.2 mM.1 A number of
pathological disorders have been correlated to abnormal levels
of Mg2+ within the body.2 For instance, low levels of Mg2+ are
associated with the progression of Parkinson’s disease, charac-
terised by a depletion in the number of dopaminergic neurons
in the brain.3 Therefore, the importance of Mg2+ in multiple
physiological conditions demands new chemical tools to inves-
tigate the storage, concentration and homeostasis of Mg2+ in
both health and disease.
Small organic fluorophores oﬀer a cheap, reliable and non-
disruptive method of cellular analysis, and have been widely
reported to detect a plethora of biomolecules and enzymes, as
well as to monitor biological processes and discriminate cell
types.4–9 Advances in fluorophore development have led to the
generation of smart or activatable probes, which are chemi-
cally designed so that their photophysical properties depend
on an external stimulus. The fine-tuning of these chemical
architectures not only allows spatiotemporal control of the
readout of the probes but also provides enhanced signal-to-
noise ratios, which boost their sensitivity in imaging studies
under fluorescence microscopy. Furthermore, when significant
diﬀerences are achieved between the readouts of activated and
non-activated fluorophores, quantitative measurements of
specific analytes or biological events can be performed. In the
context of divalent cation sensing, since the pioneering work
from Tsien et al.,10 multiple fluorescent probes have been
reported for in vivo and in vitro tracking of divalent
cations.11–13 Numerous chemical probes have been developed
to monitor the levels of Ca2+, the most abundant cation, with
only a modest number of probes being available for sensing
Mg2+. A major challenge in the development of Mg2+-respond-
ing probes is to ensure that the fluorescence signal is elicited
only in response to Mg2+ and no other divalent intracellular
cations, with Ca2+ being a major interference due to its high
intracellular levels. Mag-indo-1 and Mag-fura-2 are commer-
cially available probes based on the O-aminophenol-N,N,O-tri-
acetic acid (APTRA) chelating group, which can strongly bind
to Mg2+ as well as to other intracellular divalent cations.14
Remarkable work has been also recently undertaken by the
group of Buccella with the adaptation of APTRA to a range of
chemical scaﬀolds (e.g. HaloTag-binding molecules, ratio-
metric and red-emitting fluorophores) to improve its capabili-
ties as imaging reagents.15–17 Other chelating groups have
been reported for enhanced recognition of Mg2+ and minimal
cross-reactivity with Ca2+. Among these, the 4-oxo-4H-quinoli-
zine-3-carboxylic acid scaﬀold reported by Levy et al.18 oﬀers
good discrimination between the two major divalent ions and
can be eﬀectively conjugated to fluorophores (e.g. fluorescein)
to produce probes that respond to Mg2+ chelation by photo-
induced electron transfer (PeT).19 However, the limited cell
permeability of fluorescein hinders the use of these dyes for
visualising intracellular Mg2+ levels in live cells. In addition to
high cell permeability, the 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene (BODIPY) scaﬀold presents excellent photophysical
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features for live cell imaging,20–25 such as narrow excitation
and emission and excellent photostability. Furthermore, the
fluorescence emission of BODIPY can be fine-tuned via incor-
poration of chelating groups at the meso position, which aﬀect
intramolecular PeT and the overall emission of the
fluorophores.26–29 Therefore, we envisioned that the introduc-
tion of the 4-oxo-4H-quinolizine-3-carboxylic acid into the cell-
permeable BODIPY scaﬀold might render novel activatable
fluorophores for imaging intracellular levels of Mg2+.
Results and discussion
Rational design and chemical synthesis of Mg2+ probes
First, we synthesized the quinolizine chelating moiety 1
(Fig. 1), which incorporates a β-diketone moiety to selectively
chelate the Mg2+ ion and an aldehyde functional group for
adaptation to the synthesis of symmetric BODIPY fluoro-
phores.30 The 4-oxo-4H-quinolizine-3-carboxylic acid moiety
shows enhanced selectivity for Mg2+ over Ca2+ when compared
to other chelating groups (e.g. APTRA). The synthesis of the
BODIPY fluorophore 2 was achieved in a one-pot single reac-
tion by conjugation of the aldehyde 1 to pyrrole using slightly
modified reported procedures31 to isolate the BODIPY com-
pound 2 (Fig. 1) and examine its properties as a Mg2+-sensitive
fluorophore.
The low fluorescence quantum yield (i.e. around 2%) of
compound 2 after incubation with Mg2+ proved ineﬀective for
the detection of Mg2+ levels within the physiological range.
Such weak fluorescence emission can be explained due to the
free rotation of the quinolizine group conjugated to the meso
position, which might result in the energy of the excited state
being lost as rotational energy rather than emitted as fluo-
rescence. We assessed this hypothesis by examining the fluo-
rescence emission of compound 2 in environments of increas-
ing viscosity (Fig. S1 in ESI†). The enhancement of fluo-
rescence intensity in glycerol-containing media confirmed the
free rotation of the quinolizine group around the meso posi-
tion as a major cause for the low fluorescence quantum yield
of compound 2.
We envisioned that BODIPY probes where the fluorescence
enhancements derived from Mg2+ chelation and restricted
rotation were combined in a single molecular framework
might display suitable fluorescent quantum yields for Mg2+
detection in cells. As such, we designed and synthesized two
additional BODIPY compounds with two or four methyl substi-
tuents (3 and 4 respectively, Fig. 1). Whereas compound 3
would retain similar rotational freedom to compound 2, the
steric hindrance around the quinolizine core in compound 4
would minimise its free rotation. Compounds 3 and 4 were
synthesized by condensation of the aldehyde 1 to 2-methyl-
pyrrole or 2,4-dimethylpyrrole respectively, and isolated with
reasonable synthetic yields. The excitation and emission wave-
lengths of all quinolizine-BODIPY derivatives (2–4) are similar
(Fig. 1 and Fig. S2 in ESI†) as well as their photostability pro-
perties (Fig. S3 in ESI†). However, their fluorescence quantum
yields were significantly diﬀerent, with the tetramethyl-substi-
tuted BODIPY 4 showing the highest fluorescence quantum
yield after binding to Mg2+ (11%, Fig. 1 and Fig. S4 in ESI†).
This observation supports our rational design of BODIPY
probes combining the chelating 4-oxo-4H-quinolizine-3-car-
boxylic acid with restricted rotational features to maximise the
fluorescence response upon Mg2+ recognition.
In vitro spectral characterisation of Mg2+ binding
In view of the spectral properties of compound 4, we examined
its application for the detection and visualisation of intracellu-
lar Mg2+ levels. As shown in Fig. 2A, compound 4 showed a
dose-dependent fluorescence increase upon incubation with
concentrations of Mg2+ within its physiological range (i.e. up
to 1 mM). Furthermore, compound 4 showed excellent dis-
crimination of Mg2+ vs. other divalent cations, with around
4-fold selectivity over Ca2+-the most abundant divalent cation
found in cells and tissues- and marginal cross-reactivity with
Mn2+ and Zn2+ at their physiological concentrations (Fig. 2B
and Fig. S5 in ESI†).32,33 Mn2+ is present in cells in a relatively
broad range of concentrations (i.e. between 0.04 and 2 mM)34
whereas Zn2+ is predominantly bound as a co-factor in protein
complexes35 and found as a free cation in cells at very low con-
centrations (i.e. in the pM range). Notably, the co-incubation
with Mg2+ and the chelating agent ethylenediaminetetraacetic
acid (EDTA) did not lead to any fluorescence enhancement
(Fig. 2B). This result confirms that, together with the lack of
rotational energy loss, the blockage of the intramolecular PeT
due to Mg2+ chelation is likely to be the main mechanism
Fig. 1 Simpliﬁed synthetic scheme for the preparation of Mg-sensitive
BODIPY ﬂuorophores based on the 4-oxo-4H-quinolizine-3-carboxylic
acid chelating scaﬀold. Below are represented the chemical structures
of BODIPY ﬂuorophores 2, 3 and 4 and their corresponding activation
modes upon Mg2+ recognition. Fluorescence quantum yields were
determined relative to ﬂuorescein in basic ethanol.
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responsible for the fluorescence response of compound 4, as
reported for similar chelator-based fluorogenic probes.36–38
The fluorescence increase of compound 4 upon chelation of
Mg2+ was readily detected by the naked eye, as an indication of
its high sensitivity with a limit of detection in the low micro-
molar range (2 μM, Fig. S6 in ESI†).
Further detailed characterisation studies showed that the
Mg2+-4 adduct presented a Kd value of around 100 μM
(Fig. 3A), in the range of DCHQ-based quinoline fluoro-
phores39 and an order of magnitude lower than APTRA-based
Mg2+-responding fluorophores.16 We also analysed the fluo-
rescence response of the Mg2+-4 adduct to diﬀerent pH values
and observed no major dependence on pH (Fig. S7 in ESI†).
Finally, we compared the fluorescence response of compound
4 to both free Mg2+ as well as Mg-ATP, which is found in rela-
tively high concentrations inside metabolically active cells.40
As shown in Fig. 3B, compound 4 showed around 5-fold
brighter fluorescence emission when bound to free Mg2+ in
comparison to the same concentration of Mg-ATP, asserting its
utility to monitor changes in the levels of free Mg2+ within the
intracellular physiological range.
Fluorescence cell and tissue imaging
In view of the excellent properties of compound 4 as a Mg2+-
activatable fluorescent probe, we examined its capabilities for
cell imaging using A549 human adenocarcinoma cells. A549
cells were incubated or not with carbonyl cyanide p-(trifluoro-
methoxy)phenylhydrazone (FCCP), a molecule that acts as a
mitochondria uncoupler and leads to an increase in Mg2+ con-
centration resulting from ATP hydrolysis and/or Mg2+ eﬄux
from mitochondria.19,32 We acquired fluorescence confocal
microscopy images of both untreated and FCCP-treated cells
that had been incubated with the same concentration of com-
pound 4, and observed brighter intracellular emission in the
latter due to significantly higher intracellular Mg2+ levels
(Fig. 4 and Fig. S8 in ESI† for quantitative image analysis). We
also examined the intracellular localisation of compound 4 by
co-staining with diﬀerent subcellular markers (i.e. LysoTracker
Red and MitoTracker Red). Dual-colour images suggested that
compound 4 mainly localised in the cytoplasm of A549 cells,
with slightly preferential accumulation in the mitochondria
over lysosomal compartments (Fig. S9 in ESI†). Furthermore,
we performed cell viability experiments and confirmed that
the incubation of A549 cells with compound 4 did not induce
any significant cytotoxicity at the concentrations used for
Fig. 3 (A) Determination of the dissociation constant of the Mg2+-4
adduct by measuring the ﬂuorescence intensity of compound 4 (10 μM,
H2O : EtOH 1 : 1) at increasing concentrations of Mg
2+. Values rep-
resented as means ± s.e.m. (n = 3). Kd: 92 ± 30 μM. (B) Emission spectra
of compound 4 (50 μM) upon incubation with 2 mM free Mg2+ (green)
and 2 mM Mg-ATP (grey); λexc.: 450 nm. (Inset) Quantiﬁcation of the
ﬂuorescence intensities for both conditions. Values represented as
means ± s.d. (n = 3).
Fig. 4 Fluorescence confocal microscopy images of A549 cells upon
incubation with compound 4. Cells were pre-incubated or not with 1 μM
FCCP, and then treated with compound 4 (3 μM) for 15 min.
Fluorescence images are shown in the left panels and brightﬁeld images
on the right. Quantitative analysis of the ﬂuorescence intensity in both
conditions is shown in Fig. S8.† Scale bar: 10 μm.
Fig. 2 (A) Fluorescence emission of compound 4 (10 μM, H2O : EtOH
1 : 1) upon incubation with increasing concentrations (0, 0.1, 0.25, 0.5,
0.75 and 1 mM) of Mg2+; λexc.: 450 nm. (B) Comparative ﬂuorescence of
compound 4 upon incubation with diﬀerent divalent cations at their
respective physiological concentrations (Mg2+, Ca2+, Mn2+: 1 mM; Zn2+:
1 μM; EDTA: 5 mM). Inset: Pictograms of compound 4 under 365 nm
excitation in solutions without (left) or with Mg2+ (right). *** for
p < 0.001, n.s. for p > 0.05.
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in vitro characterisation and cell imaging (Fig. S10 in ESI†).
Altogether, these experiments assert the value of compound 4
as a fluorescent activatable probe for the detection of physio-
logical Mg2+ concentrations, both in vitro and in cells.
Finally, to examine the versatility of compound 4 for
imaging in complex biological systems, we tested it in the
plant model Arabidopsis thaliana, where Mg2+ ions accumulate
around chlorophyll biomolecules in the chloroplasts. We
applied compound 4 to the cotyledons and detected bright
green fluorescence in the vasculature of new leaves (Fig. 5).
Furthermore, high-magnification fluorescence images indi-
cated the preferential localisation of compound 4 in chloro-
phyll-rich cells, such as mesophyll cells in the vascular regions
(Fig. 5d).
Conclusions
In summary, we developed a novel BODIPY activatable fluoro-
phore for the detection and imaging of physiological concen-
trations of Mg2+ and high selectivity over other divalent
cations, such as Ca2+. The combined lack of rotational
freedom and eﬀective quinolizine-based Mg2+ chelation func-
tion as the activation mechanisms for enhanced fluorescence
amplification, enabling the imaging of free intracellular Mg2+
ions in live cells and tissues.
Experimental section
General methods
Commercially available reagents were used without further
purification. Thin-layer chromatography was conducted on
Merck silica gel 60 F254 sheets and visualized by UV (254 and
365 nm). Silica gel (particle size 35–70 µm) was used for
column chromatography. 1H and 13C spectra were recorded in
a Bruker Avance 500 spectrometer (at 500 and 125 MHz,
respectively). Data for 1H NMR spectra reported as chemical
shift δ (ppm), multiplicity, coupling constant (Hz) and inte-
gration. Data for 13C NMR spectra reported as chemical shifts
relative to the solvent peak. HPLC-MS analysis was performed
on a Waters Alliance 2695 separation module connected to a
Waters PDA2996 photodiode array detector and a ZQ Micromass
mass spectrometer (ESI-MS) with a Phenomenex® column (C18,
5 µm, 4.6 × 150 mm). Compounds were purified using a Waters
semi-preparative HPLC system using a Phenomenex® column
(C18 Axial, 10 µm, 21.2 × 150 mm) and UV detection.
Synthesis of ethyl 1-formyl-4-oxo-4H-quinolizine-3-carboxylic
acid (1)
Ethyl 1-formyl-4-oxo-4H-quinolizine-3-carboxylate (1.04 g,
0.1 mmol, 1 eq.) was dissolved in a mixture of THF (40 mL)
and EtOH (40 mL). 1 M aqueous NaOH (5 mL, 1.3 eq.) was
added and the reaction was left to stir for 2 h at r.t. Removal of
the solvents under vacuum rendered the product (1.11 g) in
quantitative yield. 1H NMR (500 MHz, D2O) δ 9.86 (d, J =
1.1 Hz, 1H), 9.37 (ddt, J = 7.3, 1.5, 0.8 Hz, 1H), 9.19 (dd, J =
9.0, 0.8 Hz, 1H), 8.58 (d, J = 0.9 Hz, 1H), 8.13–8.08 (m, 1H),
7.59 (tt, J = 7.1, 1.2 Hz, 1H) ppm. 13C NMR (125 MHz, D2O)
δ 191.1, 172.9, 157.4, 146.0, 138.7, 130.0, 122.4, 119.6,
109.4 ppm.
Synthesis and characterisation of BODIPY derivatives (2–4)
Compounds 2, 3 and 4 were synthesized using modified
reported procedures30,31 using the aldehyde 1 as the starting
material. For the synthesis of compound 2, compound 1
(150 mg, 0.63 mmol, 1 eq.) was dissolved in CH2Cl2 (50 mL),
and pyrrole (437 μL, 6.3 mmol, 10 eq.) was then added fol-
lowed by 1 drop of TFA. The reaction was left to stir overnight
under N2. Additional pyrrole (437 μL, 6.3 mmol, 10 eq.) was
then added followed by 1 more drop of TFA and the reaction
was stirred under N2 for further 7 h. Afterwards, DDQ (143 mg,
0.63 mmol, 1 eq.) in CH2Cl2 (10 mL) was added dropwise and
the reaction was left to stir for 20 min. Triethylamine (2.2 mL,
15.75 mmol, 25 eq.) followed by 48% BF3OEt2 in Et2O (1.2 mL,
9.45 mmol, 15 eq.) were added and the reaction was stirred for
3 h at r.t. under N2. Volatiles were removed under vacuum and
flash column chromatography (CH2Cl2/MeOH, 92 : 8) followed
by semi-preparative HPLC (0–100% ACN/H2O + 0.1% FA over
25 min) yielded compound 2 (2 mg) as an orange solid. 1H
NMR (500 MHz, MeOD) δ 9.54 (d, J = 7.8 Hz, 1H), 8.53–6.37
(m, 1H), 8.03 (d, J = 10.1 Hz, 1H), 8.01–7.85 (m, 2H), 7.80 (s,
1H), 7.63 (dt, J = 13.5, 6.3 Hz, 2H), 6.95 (t, J = 5.0 Hz, 1H),
6.71–6.52 (m, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 167.6,
Fig. 5 Fluorescence confocal microscopy images of Arabidopsis thali-
ana after treatment with compound 4. Fluorescence images highlight
the accumulation of compound 4 in the vasculature of new leaves upon
cotyledon loading: (a) green ﬂuorescence emission from compound 4,
(b) red ﬂuorescence emission from chlorophyll, (c) merged ﬂuorescent
images from (a) and (b) including an overlay brightﬁeld image. Scale bar:
250 μm. (d) High-magniﬁcation dual-colour image highlighting the
localisation of compound 4 in chlorophyll-rich cells in the vascular
region. Scale bar: 25 μm.
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160.2, 146.0, 145.7, 145.4, 140.0, 136.9, 136.3, 130.1, 129.7,
129.2, 124.3, 118.9, 118.5, 118.3 ppm. HRMS (ESI−) (m/z):
[M − H]− calcd for C19H11BF2N3O3 378.0861; found 378.0841.
For the synthesis of compound 3, compound 1 (150 mg,
0.63 mmol, 1 eq.) was dissolved in CH2Cl2 (50 mL), and
2-methylpyrrole (525 μL, 6.3 mmol, 10 eq.) was then added fol-
lowed by 1 drop of TFA. The reaction was left to stir overnight
under N2. Additional 2-methylpyrrole (263 μL, 3.15 mmol,
5 eq.) was then added followed by 1 more drop of TFA and the
reaction was stirred under N2 for further 7 h. Afterwards, DDQ
(143 mg, 0.63 mmol, 1 eq.) in CH2Cl2 (10 mL) was added drop-
wise and the reaction was left to stir for 20 min. Triethylamine
(2.2 mL, 15.75 mmol, 25 eq.) followed by 48% BF3OEt2 in Et2O
(1.2 mL, 9.45 mmol, 15 eq.) were added and the reaction was
stirred for 3 h at r.t. under N2. Volatiles were removed under
vacuum and flash column chromatography (CH2Cl2 : MeOH,
96 : 4) followed by semi-preparative HPLC (0–100% ACN/H2O +
0.1% FA over 25 min) yielded compound 3 (17 mg) as an
orange solid. 1H NMR (500 MHz, CD2Cl2) δ 9.48 (d, J = 7.3 Hz,
1H), 8.63 (s, 1H), 7.90 (d, J = 8.9 Hz, 1H), 7.82–7.73 (m, 1H),
7.56–7.47 (m, 1H), 6.59 (d, J = 4.1 Hz, 2H), 6.32 (d, J = 4.2 Hz,
2H), 2.68 (s, 6H) ppm. 13C NMR (125 MHz, CD2Cl2) δ 165.4,
160.1, 159.6, 144.8, 141.5, 135.3, 134.6, 129.3, 128.9, 125.6,
125.1, 124.7, 120.3, 118.9, 110.0, 14.7 ppm. HRMS (ESI+) (m/z):
[M]+ calcd for C21H16BF2N3O3 407.1253; found 407.1251.
For the synthesis of compound 4, compound 1 (26 mg,
0.1 mmol, 1 eq.) was dissolved in CH2Cl2 (5 mL), and 2,4-di-
methylpyrrole (20 μL, 0.2 mmol, 2 eq.) was then added fol-
lowed by 1 drop of TFA. The reaction was left to stir overnight
under N2. Afterwards, DDQ (23 mg, 0.1 mmol, 1 eq.) in CH2Cl2
(5 mL) was added dropwise and the reaction was left to stir for
20 min. Triethylamine (350 μL, 2.5 mmol, 25 eq.) followed by
48% BF3OEt2 in diethyl ether (185 μL, 1.5 mmol, 15 eq.) were
added and the reaction was stirred for 3 h at r.t. under N2.
Volatiles were removed under vacuum and flash column
chromatography (CH2Cl2 : MeOH, 95 : 5) followed by semi-pre-
parative HPLC (0–100% ACN/H2O + 0.1% FA over 25 min)
yielded compound 4 (13 mg) as an orange solid in a 25% yield
over the 3 steps. 1H NMR (500 MHz, CDCl3) δ 9.50 (t, J =
8.8 Hz, 1H), 8.58 (d, J = 8.1 Hz, 1H), 7.88–7.76 (m, 2H),
7.55–7.45 (m, 1H), 6.04 (s, 2H), 2.62 (s, 6H), 1.38 (s, 6H) ppm.
13C NMR (125 MHz, CDCl3) δ 165.6, 160.0, 159.7, 157.6, 144.8,
143.7, 142.0, 141.0, 135.8, 133.1, 131.9, 129.2, 123.8, 122.1,
118.7, 110.9, 14.9, 14.7 ppm. HRMS (ESI+) (m/z): [M + H]+
calcd for C23H21BF2N3O3 436.1644; found 436.1643.
In vitro spectral characterisation
Spectroscopic and quantum yield data were recorded on a
Synergy HT spectrophotometer (Biotek). Compounds were dis-
solved at the indicated concentrations and spectra were
recorded at r.t. Spectra are represented as means from at least
two independent experiments with n = 3. When applicable,
quantum yields were calculated by measuring the integrated
emission area of the fluorescence spectra and comparing it to
the area measured for fluorescein in basic ethanol as
reference.41
Fluorescence imaging in A549 cells
Human lung A549 adenocarcinoma cells (ATCC CCL-185) were
grown using Dulbecco’s Modified Eagle Medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), antibiotics (100
U mL−1 penicillin and 100 mg mL−1 streptomycin) and 2 mM
L-glutamine in a humidified atmosphere at 37 °C with 5%
CO2. A549 cells were regularly passaged in T-75 cell culture
flasks. For microscopy experiments, cells were plated on glass
chamber slides Lab-Tek™ II (Nunc) the day before imaging,
reaching 75% to 90% confluence on the day of the experiment.
For imaging experiments, cells were incubated for 15 min at
37 °C with compound 4, washed once with PBS and imaged
under a Zeiss LSM 510 META fluorescence confocal micro-
scope equipped with a live cell imaging stage. Fluorescence
and brightfield images were acquired using a 40× oil objec-
tives. Fluorescent probes were excited with 488 nm (for com-
pound 4) or 543 nm (for MitoTracker Red and LysoTracker
Red) lasers. Confocal microscopy images were analysed and
processed with ImageJ.
Fluorescence imaging in Arabidopsis
Arabidopsis thaliana seeds of the Col-0 ecotype were surface
sterilised using 10% (v/v) bleach for 10 min, followed by one
wash in 70% EtOH, and 5 rinses in sterile ddH2O. Seeds were
then plated individually on 0.5× Murashige-Skoog media, soli-
dified with 2% (w/v) Phytoagar. Seeds were stratified at 4 °C
for 3 days before being transferred to a vertical position in a
controlled growth chamber under long day conditions (16 h
light: 8 h dark), with 100 μmol m−2 s−1 white light and a con-
stant temperature of 21 °C. At 11 days after germination, plates
were placed flat to encourage the cotyledons to grow away from
the media. On day 12, the cotyledons were treated with 0.3 μL
of 2.5% (v/v) Adigor for 1 h to improve cotyledon permeability.
A 0.3 μL drop of 10 mM compound 4 was then applied to each
cotyledon and the seedlings were incubated for around 4 h.
The true leaves were then carefully removed, avoiding any
contact with the probe, and mounted on glass slides using
ddH2O. The leaves were imaged using Leica 5× HC PL Fluotar
or 20× HCX APO w objectives on a Leica TCS SP8 Confocal.
Samples were excited at 488 nm and emission collected at
500–540 nm for compound 4 and 650–705 nm for chlorophyll.
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